BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 16710036)

  • 21. Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion.
    Orezzoli JP; Sioletic S; Olawaiye A; Oliva E; del Carmen MG
    Gynecol Oncol; 2009 Jun; 113(3):316-23. PubMed ID: 19345400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bio-pathologic characteristics related to chromosome 11 aneusomy and cyclin D1 gene status in surgically resected stage I and II breast cancer: Identification of an adverse prognostic profile.
    Mottolese M; Orlandi G; Sperduti I; Merola R; Buglioni S; Di Benedetto A; Pinnarò P; Perracchio L; Venturo I; Cognetti F; Cianciulli A
    Am J Surg Pathol; 2007 Feb; 31(2):247-54. PubMed ID: 17255770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas.
    Allard JE; Risinger JI; Morrison C; Young G; Rose GS; Fowler J; Berchuck A; Maxwell GL
    Gynecol Oncol; 2007 Oct; 107(1):52-7. PubMed ID: 17582475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluorescence in situ hybridization analysis of HER-2/neu, c-myc, and p53 in endometrial cancer.
    Williams JA; Wang ZR; Parrish RS; Hazlett LJ; Smith ST; Young SR
    Exp Mol Pathol; 1999 Dec; 67(3):135-43. PubMed ID: 10600396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences.
    Soslow RA; Bissonnette JP; Wilton A; Ferguson SE; Alektiar KM; Duska LR; Oliva E
    Am J Surg Pathol; 2007 Jul; 31(7):979-87. PubMed ID: 17592263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of elevated C-reactive protein levels with an impaired prognosis in patients with surgically treated endometrial cancer.
    Schmid M; Schneitter A; Hinterberger S; Seeber J; Reinthaller A; Hefler L
    Obstet Gynecol; 2007 Dec; 110(6):1231-6. PubMed ID: 18055714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p53 as a prognostic indicator in endometrial cancer.
    Geisler JP; Wiemann MC; Zhou Z; Miller GA; Geisler HE
    Gynecol Oncol; 1996 May; 61(2):245-8. PubMed ID: 8626141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity.
    Bozzetti C; Musolino A; Camisa R; Bisagni G; Flora M; Bassano C; Martella E; Lagrasta C; Nizzoli R; Personeni N; Leonardi F; Cocconi G; Ardizzoni A
    Am J Clin Oncol; 2006 Apr; 29(2):171-7. PubMed ID: 16601438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma.
    Mano MS; Awada A; Di Leo A; Durbecq V; Paesmans M; Cardoso F; Larsimont D; Piccart M
    Gynecol Oncol; 2004 Mar; 92(3):887-95. PubMed ID: 14984957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma.
    Silverman MB; Roche PC; Kho RM; Keeney GL; Li H; Podratz KC
    Gynecol Oncol; 2000 Apr; 77(1):1-7. PubMed ID: 10739683
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic indicators of survival in advanced endometrial cancer.
    Behbakht K; Yordan EL; Casey C; DeGeest K; Massad LS; Kirschner CV; Wilbanks GD
    Gynecol Oncol; 1994 Dec; 55(3 Pt 1):363-7. PubMed ID: 7835775
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.
    van Geelen CM; Westra JL; de Vries EG; Boersma-van Ek W; Zwart N; Hollema H; Boezen HM; Mulder NH; Plukker JT; de Jong S; Kleibeuker JH; Koornstra JJ
    J Clin Oncol; 2006 Nov; 24(31):4998-5004. PubMed ID: 17075118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FIGO stage IIIC endometrial carcinoma: prognostic factors and outcomes.
    Hoekstra AV; Kim RJ; Small W; Rademaker AW; Helenowski IB; Singh DK; Schink JC; Lurain JR
    Gynecol Oncol; 2009 Aug; 114(2):273-8. PubMed ID: 19428094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant radiotherapy in incompletely staged IC and II endometrioid uterine cancer.
    Parthasarathy A; Kapp DS; Cheung MK; Shin JY; Osann K; Chan JK
    Obstet Gynecol; 2007 Dec; 110(6):1237-43. PubMed ID: 18055715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.
    Livasy CA; Reading FC; Moore DT; Boggess JF; Lininger RA
    Gynecol Oncol; 2006 Jan; 100(1):101-6. PubMed ID: 16157366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 14-3-3sigma in endometrial cancer--a possible prognostic marker in early-stage cancer.
    Ito K; Suzuki T; Akahira J; Sakuma M; Saitou S; Okamoto S; Niikura H; Okamura K; Yaegashi N; Sasano H; Inoue S
    Clin Cancer Res; 2005 Oct; 11(20):7384-91. PubMed ID: 16243811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemo-radiotherapy.
    Kuoppala T; Mäenpää J; Tomas E; Puistola U; Salmi T; Grenman S; Lehtovirta P; Fors M; Luukkaala T; Sipilä P
    Gynecol Oncol; 2008 Aug; 110(2):190-5. PubMed ID: 18534669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer.
    Secord AA; Havrilesky LJ; O'Malley DM; Bae-Jump V; Fleming ND; Broadwater G; Cohn DE; Gehrig PA
    Gynecol Oncol; 2009 Sep; 114(3):442-7. PubMed ID: 19560193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequent PIK3CA gene amplification and its clinical significance in colorectal cancer.
    Jehan Z; Bavi P; Sultana M; Abubaker J; Bu R; Hussain A; Alsbeih G; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
    J Pathol; 2009 Nov; 219(3):337-46. PubMed ID: 19697359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.
    McMeekin DS; Filiaci VL; Thigpen JT; Gallion HH; Fleming GF; Rodgers WH;
    Gynecol Oncol; 2007 Jul; 106(1):16-22. PubMed ID: 17574073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.